Key Highlights

  • Net loss per share was USD 8.52 against an estimate of a USD 1.56 loss.
  • Collaboration Revenue was USD 11.4 million, compared with USD 4.7 million.
  • Net loss was USD 38.5 million, compared with USD 21.5 million.
  • Cash and cash equivalents were USD 252 million at September 30, 2026.

Iambic Therapeutics, Inc. (NASDAQ:IAM) reported third quarter 2026 collaboration revenue of USD 11.4 million, compared with USD 4.7 million in the prior-year quarter. The company attributed the increase primarily to its discovery collaborations.

The net loss was USD 38.5 million, compared with USD 21.5 million, and net loss per share attributable to common stockholders was USD 8.52, compared with USD 5.24, against an estimate of a USD 1.56 loss. The company reported these results in a release furnished on Form 8-K dated November 16, 2026.

Third Quarter Results

Research and development expenses were USD 34.1 million, compared with USD 23.1 million. The company attributed the increase primarily to increased clinical and Manufacturing costs, discovery pipeline activity across internal Assets and new Partnership programs, and headcount growth.

General and administrative expenses were USD 7.4 million, compared with USD 4.3 million, which the company attributed primarily to headcount growth and public company readiness. Total operating expenses were USD 41.5 million, compared with USD 27.3 million, and the loss from operations was USD 30.1 million, compared with USD 22.6 million.

Interest income was USD 2.0 million, compared with USD 1.2 million. The change in Fair Value of convertible notes was a USD 10.4 million non-cash charge, related to notes that converted into common stock immediately prior to the closing of the initial public offering. Total other expense, net, was USD 8.4 million, and weighted average shares outstanding were 4,521,229.

Nine-Month Results and Partnerships

For the nine months ended September 30, 2026, collaboration revenue was USD 24.1 million, compared with USD 8.6 million, and total operating expenses were USD 107.7 million, compared with USD 66.9 million. The net loss was USD 88.6 million, compared with USD 54.6 million, and net loss per share was USD 20.37, compared with USD 13.34.

The company states that collaboration billings were approximately USD 100 million through the third quarter. It describes partnerships with AbbVie, entered in September, and Bayer, entered in June, and reports a program milestone achieved with Takeda that triggered a USD 1.0 million payment.

Cash Position and Initial Public Offering

Cash and cash equivalents were USD 252 million at September 30, 2026, compared with USD 180.5 million at December 31, 2025. The figure excludes initial public offering net proceeds of approximately USD 156 million and USD 47 million of upfront payments from AbbVie, both received in October 2026, and pro forma cash and cash equivalents were approximately USD 455 million.

In October 2026, the company closed its initial public offering of 10,781,250 shares of common stock at a public offering price of USD 16.00 per share, which included the full exercise of the underwriters' option to purchase 1,406,250 additional shares. Gross proceeds were USD 172.5 million.

Total assets were USD 332.1 million, compared with USD 195.0 million, and total liabilities were USD 207.2 million, compared with USD 40.2 million. Accounts Receivable and unbilled receivables were USD 55.8 million, compared with USD 1.3 million, and current liabilities were USD 75.9 million, compared with USD 26.3 million.

Iambic Therapeutics Q3 2026 Earnings: Key Takeaways

Iambic Therapeutics reported third quarter 2026 collaboration revenue of USD 11.4 million and a net loss of USD 38.5 million. Cash and cash equivalents were USD 252 million at September 30, 2026.